Twist Bioscience Corporation (NASDAQ: TWST) reported Q4 EPS of ($0.91), $0.36 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.78 million.

GUIDANCE:

Twist Bioscience Corporation sees Q1 2023 revenue of $54 million, versus the consensus of $57 million.

Twist Bioscience Corporation sees FY2023 revenue of $261-269 million, versus the consensus of $256 million.

• Revenue is expected to be in the range of $261 million to $269 million
• SynBio revenue is expected to be in the range of $104 million to $106 million
• NGS revenue is expected to be in the range of $120 million to $123 million
• Biopharma revenue is expected to be in the range of $37 million to $40 million
• Gross margin is expected to be approximately 39-40% for fiscal 2023
• Operating expenses including R&D and SG&A are expected to be approximately $365 million for the year
• R&D expense is expected to be approximately $138 million
• Net loss is expected to be approximately $260 million and includes:
• Stock-based compensation is expected to be approximately $83 million
• Depreciation and amortization is expected to be approximately $26 million
• Operating expenses for DNA data storage of approximately $46 million
• Capital expenditure is expected to be approximately $50 million
• FY23 Year End Cash projected to be $300M

For earnings history and earnings-related data on Twist Bioscience Corporation (TWST) click here.